Entrada Therapeutics Stock Forecast
NASDAQ: TRDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:11 AM ET
TRDA analyst consensus
Consensus (8 analysts)
none
Avg. price target
$19.00+247.35%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Entrada Therapeutics (2026-10-08), 7 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $19.00, with a high estimate of $25.00 and a low estimate of $11.00. The average target implies upside of 247.3% from the current price of $5.47.
The spread between the highest and lowest targets is 127.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TRDA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 7 | 88% |
| Hold | 1 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.00 | +101.10% |
| Average target | $19.00 | +247.35% |
| High target | $25.00 | +357.04% |